Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
1.10 MCHF
−1.890CHF
−61.98 MCHF
7.04 MCHF
28.86 M
About MOLECULAR PARTNERS N
Sector
Industry
CEO
Patrick Amstutz
Website
Headquarters
Schlieren
Employees (FY)
182
Founded
2004
ISIN
CH0256379097
FIGI
BBG00JYV5TW8
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0QXX is 3.485 CHF — it has decreased by 0.23% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange MOLECULAR PARTNERS AG CHF0.1 stocks are traded under the ticker 0QXX.
MOLECULAR PARTNERS AG CHF0.1 is going to release the next earnings report on May 16, 2024. Keep track of upcoming events with our Earnings Calendar.
0QXX stock is 0.24% volatile and has beta coefficient of 0.43. Check out the list of the most volatile stocks — is MOLECULAR PARTNERS AG CHF0.1 there?
0QXX earnings for the last quarter are −0.57 CHF per share, whereas the estimation was −0.72 CHF resulting in a 20.83% surprise. The estimated earnings for the next quarter are −0.57 CHF per share. See more details about MOLECULAR PARTNERS AG CHF0.1 earnings.
MOLECULAR PARTNERS AG CHF0.1 revenue for the last quarter amounts to 2.50 M CHF despite the estimated figure of 1.40 M CHF. In the next quarter revenue is expected to reach 400.00 K CHF.
Yes, you can track MOLECULAR PARTNERS AG CHF0.1 financials in yearly and quarterly reports right on TradingView.
0QXX net income for the last quarter is −19.78 M CHF, while the quarter before that showed −11.44 M CHF of net income which accounts for −72.92% change. Track more MOLECULAR PARTNERS AG CHF0.1 financial stats to get the full picture.
Today MOLECULAR PARTNERS AG CHF0.1 has the market capitalization of 110.44 M, it has decreased by 2.21% over the last week.
No, 0QXX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0QXX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MOLECULAR PARTNERS AG CHF0.1 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 182.00 employees. See our rating of the largest employees — is MOLECULAR PARTNERS AG CHF0.1 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MOLECULAR PARTNERS AG CHF0.1 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MOLECULAR PARTNERS AG CHF0.1 stock shows the sell signal. See more of MOLECULAR PARTNERS AG CHF0.1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MOLECULAR PARTNERS AG CHF0.1 future price: according to them, 0QXX price has a max estimate of 15.00 CHF and a min estimate of 3.00 CHF. Read a more detailed MOLECULAR PARTNERS AG CHF0.1 forecast: see what analysts think of MOLECULAR PARTNERS AG CHF0.1 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MOLECULAR PARTNERS AG CHF0.1 EBITDA is −58.69 M CHF, and current EBITDA margin is −833.87%. See more stats in MOLECULAR PARTNERS AG CHF0.1 financial statements.